Technology
Health
Biotechnology

Cellular Biomedicine Group

$17.06
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.19 (-1.10%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell CBMG and other stocks, options, ETFs, and crypto commission-free!

About

Cellular Biomedicine Group, Inc. Common Stock, also called Cellular Biomedicine Group, is a clinical stage biopharmaceutical company, which engages in the development of new treatments for cancerous and degenerative diseases utilizing proprietary cell-based technologies. Read More Its technology includes immune system therapy for treatment of cancer indications and human adipose-derived mesenchymal progenitor cells (haMPC) for treatment of joint and autoimmune diseases. The company was founded in 2009 and is headquartered in New York, NY.

Employees
193
Headquarters
New York, New York
Founded
2009
Market Cap
326.31M
Price-Earnings Ratio
โ€”
Dividend Yield
0.00
Average Volume
61.94K
High Today
$17.50
Low Today
$16.92
Open Price
$17.34
Volume
11.15K
52 Week High
$25.00
52 Week Low
$12.04

Collections

Technology
Health
Biotechnology
Medical
Biopharmaceutical
Therapy
Cancer Prevention
Pharmaceutical

News

Seeking AlphaMay 4

Cellular Biomedicine Group, Inc. (CBMG) CEO Tony Liu on Q1 2019 Results - Earnings Call Transcript

Cellular Biomedicine Group, Inc. (NASDAQ:CBMG) Q1 2019 Earnings Conference Call May 1, 2019 8:30 AM ET Company Participants Tony Liu - Executive Director, CEO, CFO Derrick Li - Head of Strategy & IR Conference Call Participants Madhu Kumar - Robert W. Baird George Zavoico - B. Riley FBR Operator Greetings and welcome to Cellular Biomedicine First Quarter 2019 Earnings Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal prese...

13
Markets InsiderApr 30

Cellular Biomedicine Group Reports First Quarter 2019 Results and Highlights Operational Progress

NEW YORK and SHANGHAI, April 30, 2019 /PRNewswire/ -- Cellular Biomedicine Group, Inc. (Nasdaq: CBMG) ("CBMG" or the "Company"), a biopharmaceutical firm engaged in the drug development of immunotherapies for cancer and stem cell therapies for degenerative diseases, today reported its financial results and business highlights for the first quarter ended March 31, 2019. "Early in 2019, we achieved the first of many milestones anticipated for this year in support of our immuno-oncology platform, as we initia...

8
PR NewswireApr 29

Cellular Biomedicine Group Announces Results of 2019 Annual Meeting of Stockholders

9

Earnings

-$0.56
-$0.52
-$0.48
-$0.44
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
โ€”
Actual
Expected Aug 6, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.